Toronto - Delayed Quote ? CAD Aptose Biosciences Inc. (APS.TO) Follow Compare 0.5300 +0.0100 (+1.92%) At close: November 1 at 2:34 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Aptose Announces Results from Special Meeting of Shareholders SAN DIEGO and TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing tuspetinib, a highly differentiated oral kinase inhibitor for the treatment of patients with acute myeloid leukemia (AML), announced the voting results from its special meeting of shareholders held today, September 5, 2024 (the “Meeting”). A total of 6,052,460 common shares of the Company (the "Shares"), rep GlobeNewswire ? last month APTO Aptose Biosciences secures funds for AML treatment development Tuspetinib will be assessed as a frontline triplet therapy for newly diagnosed AML patients. Pharmaceutical Technology ? last month APTO Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib Proceeds to be used for development of lead compound tuspetinib in combination therapy as frontline treatment for newly diagnosed AML patientsSAN DIEGO and TORONTO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing tuspetinib, a highly differentiated oral kinase inhibitor for the treatment of patients with acute myeloid leukemia (AML), today announced that it received a $10 millio GlobeNewswire ? 2 months ago APTO Aptose Announces Adjournment of its Special Meeting of Shareholders SAN DIEGO and TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that its special meeting of shareholders (the "Meeting") convened on August 15, 2024, at 1:00 p.m. (ET) has been adjourned to September 5, 2024 at 1 p.m. (ET), without business being considered, due to a lack of quor GlobeNewswire ? 2 months ago APTO Aptose Biosciences: Q2 Earnings Snapshot TORONTO (AP) — Aptose Biosciences Inc. APTO) on Thursday reported a loss of $7.3 million in its second quarter. The Toronto-based company said it had a loss of 43 cents per share. Associated Press Finance ? 2 months ago APTO Aptose Reports Results for the Second Quarter 2024 TUS+VEN+HMA Triplet Protocol in Frontline Therapy for Newly Diagnosed AML was Reviewed by the FDA and Allowed to Proceed Abstract Supporting Exploration of the TUS+VEN+AZA Triplet in Frontline Therapy for Newly Diagnosed AML has been Submitted to the 2025 Annual Meeting of the American Society of Hematology (ASH) SAN DIEGO and TORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company develo GlobeNewswire ? 2 months ago APTO Aptose Announces Receipt of Deficiency Notice from Nasdaq SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that it has received a deficiency letter (the "Deficiency Letter") from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, for the last thirty (30) cons GlobeNewswire ? 3 months ago APTO Aptose Announces Results from Annual and Special Meeting of Shareholders SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the voting results from the Company’s annual and special meeting of shareholders held today, June 18, 2024 (the “Meeting”). A total of 8,101,527 common shares of the Company, representing 49.67% of the common share GlobeNewswire ? 4 months ago APTO Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational Drugs in AML TUS Monotherapy and TUS+VEN Doublet Therapy Active in Difficult-to-treat Genetic Subgroups, FLT3 Wildtype AML TUS Shown to Target VEN Resistance Mechanisms and Retain Activity on VEN-Resistant AML Cells in Preclinical Study TUS+VEN+Azacitidine (AZA) Triplet Trial to T GlobeNewswire ? 4 months ago APTO Aptose Biosciences (APTO) Upgraded to Buy: What Does It Mean for the Stock? Aptose Biosciences (APTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Zacks ? 4 months ago APTO Aptose Closes U$4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Aptose Closes U$4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PREMIUM MT Newswires ? 4 months ago APTO Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules SAN DIEGO and TORONTO, June 03, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 3,855,000 of its common shares (or common share equivalents in lieu thereof) at a purchase price of $1.15 GlobeNewswire ? 4 months ago APTO Aptose Biosciences Down 14% In US Premarket As Plans to Raise Near $4.4 Million Via Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Aptose Biosciences Down 14% In US Premarket As Plans to Raise Near $4.4 Million Via Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PREMIUM MT Newswires ? 4 months ago APTO Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market?Under Nasdaq Rules SAN DIEGO and TORONTO, May 31, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that it has entered into a definitive agreement for the issuance and sale of 3,855,000 of its common shares (or common share equivalents in lieu thereof) at a purchase price of $1.15 per share (or per common share equ GlobeNewswire ? 4 months ago APTO Aptose Biosciences Q1 Net Loss Falls, on Lower Expenses Aptose Biosciences Q1 Net Loss Falls, on Lower Expenses PREMIUM MT Newswires ? 5 months ago APTO Aptose Reports Results for the First Quarter 2024 TUS+VEN+HMA Triplet Protocol in 1L Therapy for Newly Diagnosed AML was Submitted to the FDA During Q1 and is Now Being Activated at Clinical Sites TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed AML is Supported by Extensive TUS and TUS+VEN Data from Completed Trials with R/R AML Conference Call and Webcast at 5:00 pm ET Today SAN DIEGO and TORONTO, May 14, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncolog GlobeNewswire ? 5 months ago APTO Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024 SAN DIEGO and TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 14, 2024, after the close of the market, and provide a corporate update. In addition, Rafael Bejar, MD, PhD, the Company’s Chief Medical Officer and resident Key Opinion GlobeNewswire ? 5 months ago APTO What Makes Aptose Biosciences (APTO) a New Buy Stock Aptose Biosciences (APTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Zacks ? 6 months ago APTO Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call Transcript Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call Transcript March 26, 2024 Aptose Biosciences Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. My name is Jonathan and I will be your conference operator today. I would like […] Insider Monkey ? 7 months ago APTO Aptose Reports Results for the Fourth Quarter and Full Year 2023 Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AMLTuspetinib Continues Broad Activity Across Mutations with Excellent Safety ProfileLuxeptinib G3 Formulation Achieves Desired Levels and Positions for Future TrialsConference Call and Webcast at 5:00 pm ET Today SAN DIEGO and TORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated or GlobeNewswire ? 7 months ago APTO Performance Overview Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index Return APS.TO S&P/TSX Composite index YTD -84.18% +15.73% 1-Year -86.05% +28.51% 3-Year -98.63% +15.30%
